Compliance With Hepatocellular Carcinoma Surveillance Guidelines Associated With Increased Lead-Time Adjusted Survival of Patients With Compensated Viral Cirrhosis: A Multi-Center Cohort Study by C.E. Costentin et al.
Compliance With Hepatocellular Carcinoma Surveillance
Guidelines Associated With Increased Lead-Time Adjusted
Survival of Patients With Compensated Viral Cirrhosis: A
Multi-Center Cohort Study.
Submitted by Beatrice Guillaumat on Wed, 01/30/2019 - 12:14
Titre
Compliance With Hepatocellular Carcinoma Surveillance Guidelines Associated With
Increased Lead-Time Adjusted Survival of Patients With Compensated Viral Cirrhosis:
A Multi-Center Cohort Study.
Type de
publication Article de revue
Auteur
Costentin, Charlotte E [1], Layese, Richard [2], Bourcier, Valérie [3], Cagnot, Carole
[4], Marcellin, Patrick [5], Guyader, Dominique [6], Pol, Stanislas [7], Larrey,
Dominique [8], de Ledinghen, Victor [9], Ouzan, Denis [10], Zoulim, Fabien [11],
Roulot, Dominique [12], Tran, Albert [13], Bronowicki, Jean-Pierre [14], Zarski, Jean-
Pierre [15], Riachi, Ghassan [16], Calès, Paul [17], Péron, Jean-Marie [18], Alric,
Laurent [19], Bourlière, Marc [20], Mathurin, Philippe [21], Blanc, Jean-Frédéric [22],
Abergel, Armand [23], Serfaty, Lawrence [24], Mallat, Ariane [25], Grangé, Jean-
Didier [26], Attali, Pierre [27], Bacq, Yannick [28], Wartelle, Claire [29], Dao, Thong
[30], Thabut, Dominique [31], Pilette, Christophe [32], Silvain, Christine [33],
Christidis, Christos [34], Nguyen-Khac, Eric [35], Bernard-Chabert, Brigitte [36],
Zucman, David [37], Di Martino, Vincent [38], Sutton, Angela [39], Letouzé, Eric [40],
Imbeaud, Sandrine [41], Zucman-Rossi, Jessica [42], Audureau, Etienne [43], Roudot-
Thoraval, Françoise [44], Nahon, Pierre [45], ANRS CO12 CirVir Group [46]
Editeur Elsevier










Aged [47], Antiviral Agents [48], Carcinoma, Hepatocellular [49], Early Detection of
Cancer [50], Female [51], Follow-Up Studies [52], France [53], Guideline Adherence
[54], Hepacivirus [55], hepatitis B virus [56], Humans [57], Kaplan-Meier Estimate
[58], Liver [59], Liver Cirrhosis [60], Liver neoplasms [61], Male [62], Middle Aged




BACKGROUND & AIMS: Semi-annual surveillance for hepatocellular carcinoma
(HCC) is recommended for patients with cirrhosis. We aimed to determine how
compliance with HCC surveillance guidelines affects survival times of patients with
hepatitis C virus- or hepatitis B virus-associated compensated cirrhosis who
developed HCC.
METHODS: We collected data from the prospective ANRS CO12 CirVir study, from
March 2006 through June 2012, on 1671 patients with biopsy-proven viral cirrhosis
and no previous liver complications who were undergoing surveillance for HCC at 35
centers in France. Only 216 patients who developed HCC during the follow-up period
were included in the analysis. Patients were considered to be compliant with
surveillance guidelines if the time between their last surveillance image evaluation
and diagnosis of HCC were fewer than 7 months and noncompliant if this time was 7
months or longer.
RESULTS: HCC was detected in 216 patients, at a median follow-up time of 59.7
months. Of these patients, 140 (80.5%) were Barcelona Clinic Liver Cancer stage 0/A,
135 (69.9%) received first-line curative treatment (15 underwent transplantation, 29
underwent resection, 89 received percutaneous ablation, and 2 received resection
and percutaneous ablation), and 129 (60.0%) were compliant with surveillance
guidelines. Seventy-nine of the patients with HCC died; 49 deaths were associated
with tumor progression. After lead-time adjustment, overall survival (OS) time was
longer in patients compliant with surveillance guidelines (median OS time, 53.2
months) than noncompliant patients (median OS time, 25.4 months) (P = .0107); this
difference remained significant even when we changed lead time assumptions. In
multivariate analysis adjusted for a propensity score, compliance with HCC
surveillance guidelines was associated with low tumor burden, allocation of curative
treatment, and increased OS time compared with noncompliance (hazard ratio for
OS, 2.19; 95% confidence interval, 1.16-4.14; P = .0150).
CONCLUSIONS: In an analysis of data from the ANRS CO12 CirVir cohort, we
associated compliance with HCC surveillance guidelines (fewer than 7 months
between image evaluations) with early diagnosis, allocation of curative treatment,
and longer adjusted OS of patients with hepatitis C virus- or hepatitis B virus-
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